Daiichi Sankyo to close Japanese RnD subsidiary Daiichi Sankyo RD Novare
Advertisement
Tokyo: Daiichi Sankyo has announced that it has decided to close its Japanese research and development (R&D) subsidiary, Daiichi Sankyo RD Novare Co., Ltd. (headquartered in Edogawa-ku, Tokyo; hereinafter called “RD Novare”).
Daiichi Sankyo will absorb RD Novare's functions into its own organization further to strengthen its R&D capabilities. RD Novare (approx. 400 employees) was founded as Daiichi Sankyo RD Associe Co., Ltd. in 2006 to support Daiichi Sankyo’s drug discovery and clinical development.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.